Stock Ratings / Health Care / SBC / insiders

STLN (38) AHCO (35) SRTA (37) AUNA (47) ⌘ Pro Terminal →

SBC Medical Group Holdings Incorporated (SBC) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$5.28 -7.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.22

SBC Medical Group Holdings Incorporated (SBC) earns a Roarable Rating of B (Buy) with 75/100 RQD Confidence. High-quality cash engine (73% profit margin, 63% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 75/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.4% avg 90D alpha vs SPY • 69.7% hit rate) →

ROARABLE B • BUY Cap $585.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SBC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SBC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, SBC Medical Group Holdings Incorporated (NASDAQ: SBC) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $5.28 (-7.29% 1D, market cap $585.2M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, SBC ranks #43 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SBC compare to STLN and AHCO in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), SBC carries a Roarable B (75/100 RQD), trailing P/E of 11.5x, gross margin of 73.3%, and ROIC of 63.1%. By comparison, STLN (Starling Oncology Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $677.7M) and AHCO (AdaptHealth Corp.) posts a D- grade (35/100 RQD, P/E N/A, ROIC 2.2%, cap $808.5M). Among the 5-stock peer group, SRTA leads on earnings multiple (10.2x) while SBC leads on capital efficiency (63.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SBC?

▼

Per SBC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001930313), SBC Medical Group Holdings Incorporated generated $173.6M in revenue (-15.5% YoY), $51.0M in net income, and $23.3M in free cash flow against $380.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (73% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.22 (-1.07%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 13.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 75/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.4% avg 90D alpha vs SPY • 69.7% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+7.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SBC)Realized 20D OHLCV Swing Band: ±10.6%

Deterministic 5-Pillar Attribution (75/100 Composite)

🔍 WHY SBC SCORES 75/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 13.4% FCF Margin ($23.3M FCF) & 73.3% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+16/20 pts (21% of score)

SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk13/20 pts (-7 pt drag)

Balance-sheet & 10-K footnote risk deducts 7 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade A$5.39-0.6% Next Q

Q2 (-2Q)

Grade A-$5.36+0.2% Next Q

Q3 (-1Q)

Grade A-$5.37-1.7% Next Q

Current

Grade B$5.28+7.4% Hist 90D α

Trajectory: A (83) → B (75)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the SBC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 75/100 (B) score, SBC faces multiple-compression risk if 11.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 70.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($4.90) or 200D SMA ($3.92) invalidates the momentum regime and cuts Target Base ($5.68) toward Bear Floor ($4.33).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SBC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SBC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 75%NO 25%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SBC Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SBC)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SBC. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (SBC Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SBC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +60.98%▲ ASCENDING CHANNEL

2026-11-02O $5.45H $5.69L $5.28C $5.28VOL 259.0K

RES: $5.98SUP: $2.99SMA50: $4.90SMA200: $3.92

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SBC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SBC Butterfly Map → + Track SBC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

1.6%/yr Implied 5Y Growth

vs. -15.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SBC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SBC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SBC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SBC)

Health Care Rank #43 of 1016 ⚔️ STLN vs SBC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SBC vs. STLN, AHCO, SRTA, AUNA)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SBC Medical Group Holdings Incorporated (SBC) ranks #43 by composite RQD confidence (75/100, grade B) and #425 by equity capitalization ($585.2M). Within this direct 5-issuer industry benchmark cohort, SRTA leads on earnings valuation at 10.2x trailing P/E, while SBC leads on capital efficiency and profitability with 63.1% ROIC and 73.3% gross margin. SBC currently leads its immediate peer cohort in composite quantitative strength at 75/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SBC ACTIVE SBC Medical Group Holdings Incorporated	B	75/100	11.5x	73.3%	63.1%	-7.29%	$585.2M	Benchmark Subject
STLN Starling Oncology Inc.	D-	38/100	—	—	-35.0%	-1.80%	$677.7M	/stln-vs-sbc →
AHCO AdaptHealth Corp.	D-	35/100	—	18.8%	2.2%	-2.02%	$808.5M	/ahco-vs-sbc →
SRTA Strata Critical Medical Inc. (Class A)	D-	37/100	10.2x	20.9%	-7.1%	-6.53%	$420.2M	/srta-vs-sbc →
AUNA Auna SA (Class A)	D	47/100	—	—	—	-6.04%	$355.3M	/auna-vs-sbc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001930313

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SBC Medical Group Holdings Incorporated (SBC) reported GAAP revenue of $173.6M (-15.5% vs. FY2024 revenue of $205.4M , and -10.3% cumulative change since FY2023) , GAAP net income of $51.0M, operating cash flow of $24.7M, and free cash flow of $23.3M (+29.1% YoY). On the balance sheet, SBC closed FY2025 with $380.4M in total assets against $0 in total debt (Altman Z-Score: 5.46, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$173.6M	$51.0M	$24.7M	$23.3M	$380.4M	—
FY2024 (FY)	2024-12-31	$205.4M	$46.6M	$20.6M	$18.0M	$266.1M	—
FY2023 (FY)	2023-12-31	$193.5M	$39.4M	$50.7M	$50.7M	—	—

3. SBC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SBC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SBC compare to STLN and AHCO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SBC?

Where is SBC trading relative to its 50-day, 200-day, and 52-week technical levels?

SBC last traded at $5.28 (-7.29% on volume of 155,303 shares), positioning the stock +7.76% above its 50-day simple moving average ($4.90) and +34.69% above its 200-day simple moving average ($3.92). Across its 52-week range of $2.78 to $5.79, SBC sits at the 83.1% percentile with a 14-day RSI of 59.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.6% ($4.72 to $5.84).

SBC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are SBC insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SBC leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Direct Sub-Reports: SBC RQD Cockpit SBC 12M Forecast SBC Earnings & Move SBC Dividends & DRIP SBC Insiders & 13F SBC Whale Options SBC Profit Sankey SBC News & Why